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Introduction
Obesity is a global health problem that poses a major risk factor 
for life-threatening diseases such as cardiovascular disease, can-
cer, and neurodegeneration. Recent GWAS have identified loci 
associated with obesity in humans, paving the way for potential 
therapeutic strategies to combat metabolic disorders (1–4). How-
ever, the molecular mechanisms of many novel loci associated 
with metabolic traits remain poorly understood, mandating func-
tional studies to elucidate their mode of action. One such example 
is SORL1, the gene encoding sorting-related receptor with type A 
repeats (SORLA).
SORLA is a member of the VPS10P domain receptor gene 
family, a group of type 1 transmembrane receptors that traf-
fic target proteins among the Golgi apparatus, cell surface, and 
endosomes in various mammalian cell types (reviewed in ref. 
5). SORLA is best known for its function as a sorting protein for 
the amyloid precursor protein (APP), the main etiologic agent in 
Alzheimer’s disease (AD). SORLA-mediated sorting of APP pre-
vents proteolytic breakdown of APP into neurotoxic amyloid-β 
peptides, protecting the brain from neurodegenerative processes 
(6, 7). The genome-wide association of SORL1 gene variants with 
sporadic AD confirms the relevance of SORLA for neurodegen-
erative disease in the human population (8). Surprisingly, recent 
GWAS have also associated SORL1 with several metabolic traits 
(e.g., obesity, waist circumference) in humans and in mouse mod-
els, suggesting a function for this receptor in metabolic regulation 
(2, 9). How exactly SORLA affects energy homeostasis and the 
occurrence of obesity remains to be clarified.
Studying mouse models with loss of function or tissue-specif-
ic overexpression of SORLA as well as obese human subjects, we 
identified a role for this receptor in the control of lipid turnover in 
adipose tissue. Specifically, SORLA facilitates functional expres-
sion of the insulin receptor (IR) to promote insulin-dependent 
suppression of lipolysis in adipocytes. Overexpression of SORLA 
in adipose tissue blocks hydrolysis of triacylglycerides to free fatty 
acids (FFAs) and enhances fat deposition. In contrast, Sorl1 gene 
inactivation accelerates FFA release from triacylglycerides and 
protects mice from diet-induced obesity.
Results
Loss of SORLA reduces white adipose tissue deposition in mice. GWAS 
identified single nucleotide polymorphisms in chromosomal loci 
in the proximity of SORL1 as being associated with waist circum-
ference in humans (2) and with body fat percentage in mice (9). 
To substantiate SORL1 as the gene responsible for these meta-
bolic traits, we analyzed weight and body composition of Sorl1–/– 
mice that are genetically deficient for this receptor (referred to as 
SORLA KO) (6). When placed on a high-fat diet (HFD), SORLA 
KO animals showed a reduced gain in body weight compared with 
Sorl1+/+ littermate controls that express the receptor (referred to as 
SORLA WT) (Figure 1A). Although no obvious difference in body 
weight was seen on normal chow (Figure 1B), an inherent defect in 
acquisition of body fat was already apparent in normal chow–fed 
SORLA KO animals after their body composition was evaluated 
In humans, genetic variation of sortilin-related receptor, L(DLR class) A repeats containing (SORL1), which encodes the 
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relevance of SORLA for the determination of fat mass in mice, 
further substantiating the association of the Sorl1 locus with 
obesity-related traits in mouse models (9). SORLA is expressed 
in several tissues relevant for metabolic control, including hypo-
thalamus, liver, and skeletal muscle as well as white and brown 
adipose tissues (Supplemental Figure 3A). To identify the cell 
type responsible for SORLA-dependent control of fat mass, we 
devised an experimental model of tissue-specific overexpres-
sion of the receptor in vivo. To do so, we used a mouse model car-
rying an inducible human SORL1 cDNA construct in the Rosa26 
locus that we had generated previously (Sorl1+/+ Rosa26TgSORL1WT) 
(11). We crossed this mouse line with the adiponectin-Cre strain 
(Tg(Adipoq-Cre)1Evdr/J) directing Cre recombinase activity to adipo-
cytes (Supplemental Figure 3B). In line with this strategy, Cre-
mediated removal of the transcription stop site preceding the 
SORLA expression cassette in Rosa26 resulted in overexpres-
sion of human SORLA in adipose tissues, but not in hypothala-
mus, liver, or muscle in Sorl1+/+ Rosa26TgSORL1WT Tg(Adipoq-Cre)1Evdr/J 
animals (referred to as SORLA Tg) (Supplemental Figure 3C). 
SORLA Tg mice were compared with Sorl1+/+ Rosa26+/+ Tg(Adipoq-
Cre)1Evdr/J littermate controls carrying the Cre transgene, but lack-
ing the SORL1 cDNA construct in their germ line (referred to as 
SORLA WT/Cre). Similar to the subcellular pattern seen for the 
endogenous murine receptor, the pattern in human SORLA was 
largely confined to intracellular vesicles in adipocytes of SORLA 
Tg mice as shown by immunohistology (Supplemental Figure 
by NMR. At both at 5 and 12 months of age, chow-fed SORLA KO 
mice showed a decrease in fat and a concomitant increase in lean 
body mass compared with littermate controls (Figure 1C). This 
alteration in body composition was not due to changes in food 
intake, locomotor activity, or heat production, as these parameters 
were comparable in SORLA WT and SORLA KO mice (Supple-
mental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI84708DS1). Together, these findings sug-
gested the presence of an inherent defect in the accumulation of 
fat tissue mass in SORLA KO animals even on a normal diet.
Earlier work documented the ability of SORLA to bind lipo-
protein lipase (LpL), the enzyme responsible for hydrolysis of tri-
acylglycerides in circulating lipoproteins (10). To explore potential 
changes in systemic lipoprotein metabolism in SORLA KO mice, 
we characterized the plasma lipid levels and lipoprotein profiles 
in mice on a normal chow diet. SORLA KO mice showed a modest 
increase in FFAs and a concomitant decrease in triacylglyceride 
levels compared with SORLA WT animals. While plasma choles-
terol levels were also slightly elevated (Table 1), the lipoprotein 
profiles were indistinguishable when comparing both genotypes 
(Supplemental Figure 2, A and B). Also, no difference in LpL activ-
ity was detected in postheparin plasma or in white or brown adi-
pose tissues in SORLA KO compared with SORLA WT animals 
(Supplemental Figure 2C).
Overexpression of SORLA in adipocytes promotes obesity in 
humans and mouse models. So far, our studies confirmed the 
Figure 1. Loss of SORLA protects from diet-induced obesity. (A) Gain of body weight of SORLA WT and SORLA KO mice placed on a HFD at 35 weeks of 
age (n = 11–12 animals per genotype; 2-way ANOVA; P = 0.02 for genotypes). (B) Weight gain of SORLA WT and SORLA KO mice on normal chow. (C) Lean 
and fat tissue mass (% of total body weight) in SORLA WT and SORLA KO mice on normal chow as determined by NMR at 5 and 12 months of age. SORLA 
KO mice show an increase in lean and a concomitant decrease in fat tissue mass compared with SORLA WT animals. n = 5–6 animals per genotype.  
*P < 0.05; **P < 0.01, unpaired Student’s t test.
Table 1. Plasma lipid parameters in mice on normal chow
Lipid parameters SORLA WT SORLA KO
FFAs (nmol/ml) 455.38 ± 35.55 (n = 32) 595.35 ± 32.56 (n = 33) P < 0.01
Triacylglyceride (mg/dl) 118.03 ± 7.03 (n = 45) 100.48 ± 3.90 (n = 44) P < 0.05
Cholesterol (μg/ml) 156.30 ± 6.26 (n = 23) 187.46 ± 6.50 (n = 21) P < 0.01
Lipid parameters SORLA WT/Cre SORLA Tg
FFAs (nmol/ml) 498.13 ± 27.33 (n = 18) 574.78 ± 35.87 (n = 19) NS
Triacylglyceride (mg/dl) 104.22 ± 8.07 (n = 18) 103.34 ± 11.06 (n = 19) NS
Cholesterol (μg/ml) 107.01 ± 9.77 (n = 18) 138.63 ± 9.68 (n = 19) NS
Levels of the indicated lipids were determined using commercial ELISA kits in the plasma of male mice on normal chow (as detailed in Methods). Unpaired 
Student’s t tests were used. Comparison of Sorl1+/+ (SORLA WT) and Sorl1–/– (SORLA KO) mice and comparison of Sorl1+/+ Rosa26+/+ Tg(Adipoq-Cre)1Evdr/J (SORLA 
WT/Cre) and Sorl1+/+ Rosa26TgSORL1WT Tg(Adipoq-Cre)1Evdr/J (SORLA Tg) mice.
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animals exhibited excessive lipid accumulation in muscle and liv-
er compared with SORLA WT/Cre littermates, supportive of overt 
obesity in mice overexpressing SORLA (Supplemental Figure 6A). 
Hypertrophy of adipocytes and lipid accumulation in muscle and 
liver were also observed in SORLA WT as compared with SORLA 
KO littermates (Supplemental Figure 6B).
The diet-induced obesity caused by overexpression of SORLA 
in adipose tissue resulted in increased fasting plasma glucose 
(Supplemental Figure 7A) and insulin (Supplemental Figure 7B) 
levels in SORLA Tg compared with SORLA WT/Cre control mice. 
Impaired glucose handling in SORLA Tg mice on a HFD was sub-
stantiated by decreased clearance of glucose during glucose tol-
erance test (Supplemental Figure 7, C and D). No differences in 
fasting plasma glucose and insulin levels (Supplemental Figure 
7, A and B) or in glucose tolerance (Supplemental Figure 7, C and 
D) were seen when comparing SORLA Tg and SORLA WT/Cre 
animals on normal chow. In line with being protected from diet-
induced obesity, SORLA KO animals on HFD showed significantly 
lower levels of fasting plasma glucose and insulin levels compared 
with their respective SORLA WT littermate controls (Supplemen-
tal Figure 7, E and F). No differences in fasting plasma glucose and 
insulin levels or in the glucose tolerance test were seen when com-
paring SORLA KO and SORLA WT mice on normal chow (Supple-
mental Figure 7, E–H).
SORLA levels correlate with BMI in humans. Thus far, our stud-
ies have identified a positive correlation of SORLA levels in adi-
pocytes with the extent of fat tissue acquisition in mouse models. 
While this SORL1 gene dosage effect was already apparent on 
normal chow, the phenotype was further exacerbated by HFD 
feeding and resulted in overt obesity and secondary metabolic 
disturbances (e.g., glucose intolerance) in mice with high levels 
of receptor expression (SORLA Tg). Because all metabolic phe-
notypes seen in SORLA KO mice were contrasted by conditional 
overexpression of SORLA in adipose tissue in SORLA Tg animals, 
we reasoned that a primary role of the receptor in control of adi-
pocyte metabolism is to underlie its impact on obesity. The rel-
3D). This distribution is prototypical for SORLA and reflects its 
role in directing vesicular trafficking of target proteins between 
Golgi and endosomes (12).
Next, we performed comparative analyses of weight and 
body composition in SORLA Tg, SORLA WT/Cre, SORLA WT, 
and SORLA KO animals. As no obvious phenotypic differences 
were seen comparing Sorl1+/+ mice without (SORLA WT) or with 
the adiponectin-Cre transgene (SORLA WT/Cre) using unpaired 
Student’s t test, data obtained in both control lines were com-
bined in a control strain data set (referred to as SORLA CTR). 
Similarly to what we observed for the comparison of SORLA WT 
and SORLA KO mice as shown in Figure 1 above, no difference 
in body weight was seen when comparing all genotypes on a nor-
mal chow diet (Figure 2A). Still, the genotype-dependent acqui-
sition of fat tissue mass was already apparent, with the weights 
of subcutaneous and gonadal fat pads being highest in SORLA 
Tg and lowest in SORLA KO. SORLA CTR animals showed an 
intermediate phenotype (Figure 2B). No differences in plasma 
lipid levels (Table 1) or in lipoprotein profiles (Supplemental Fig-
ure 4) were seen when comparing SORLA Tg mice and SORLA 
WT/Cre littermates on normal chow. Also, SORLA Tg animals 
showed normal food intake, levels of activity, and heat produc-
tion when compared with SORLA WT/Cre littermates (Supple-
mental Figure 5).
HFD feeding exacerbates obesity and causes glucose intolerance 
in mice overexpressing SORLA. The effect of SORLA in promoting 
fat tissue acquisition seen on normal chow (Figure 2B) was aggra-
vated by HFD feeding of mice for 15 weeks. This dietary stress 
resulted in a higher increase in body weight gain in SORLA Tg 
animals (Figure 2C) and a more pronounced shift from lean to fat 
tissue mass (Figure 2D) as compared with SORLA KO animals. 
Again, SORLA CTR mice showed intermediate phenotypes (Fig-
ure 2, C and D). Plasma lipid levels were not significantly different 
comparing all genotypes (Table 2). However, histological analysis 
showed massive hypertrophy as well as extensive tissue remodel-
ing in white adipose tissue (WAT) of SORLA Tg mice. Also, these 
Figure 2. Overexpression of SORLA in adipose tissue exac-
erbates fat tissue acquisition. (A) Weight gain of mice of 
the indicated SORLA genotypes on normal chow. (B) Weight 
of subcutaneous WAT (sWAT) and gonadal WAT (gWAT) in 
mice of the indicated genotypes on normal chow. n = 6–7 
per genotype. ***P < 0.001, 1-way ANOVA. No statistically 
significant differences in parameters shown in A and B 
were noted when comparing SORLA WT and SORLA WT/
Cre mice (P > 0.05, unpaired Student’s t test). Thus, these 2 
genotype groups were combined as the control group (CTR). 
(C) Gain in body weight of mice of the indicated genotypes 
placed on HFD at 20 week of age. n = 5–6 animals per 
genotype. P < 0.001 for genotype, 2-way ANOVA. (D) Lean 
and fat tissue mass (% of total body weight) as determined 
by NMR in mice fed with HFD for 15 weeks. SORLA levels 
positively correlate with an increase in fat and a concomi-
tant decrease in lean tissue mass when comparing SORLA 
KO, SORLA CTR, and SORLA Tg animals. n = 9–10 animals 
per genotype. *P < 0.05, 1-way ANOVA.
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In adipose tissue explants, the amounts of intracellular and 
released FFAs were negatively correlated with SORLA activity, 
with the highest levels seen in SORLA KO, intermediate levels in 
SORLA CTR, and the lowest levels in SORLA Tg animals (Figure 
4A). This finding suggested reduced lipolytic activity in adipocytes 
(over)expressing SORLA. This assumption was supported by the 
amount of released glycerol, the second product of lipolysis, that 
was also negatively correlated with SORLA levels comparing Sorl1 
genotypes (Figure 4A). Lipidomics analyses identified a number 
of FFAs being increased in WAT of SORLA KO animals compared 
with the other genotypes (Supplemental Figure 8A). The same 
fatty acids were also increased in the plasma of SORLA KO mice 
(Supplemental Figure 8B). Excessive FFAs in mice with lower 
SORLA levels were likely deposited in peripheral tissues, as sug-
gested by increased FFA concentrations in muscle of SORLA KO 
(0.468 ± 0.02 nmol/mg tissue) versus SORLA WT controls (0.396 
± 0.02 nmol/mg tissue, P < 0.05) or in SORLA WT/Cre (0.514 ± 
0.03 nmol/mg tissue) versus SORLA Tg (0.404 ± 0.02 nmol/mg 
tissue, P < 0.05) mice on a normal chow diet.
In adipocytes, 3 intracellular lipases act in a sequential fashion 
to break down triacylglycerides to FFAs and glycerol (reviewed in 
refs. 13, 14). Initial hydrolysis of triacylglycerides to diacylglycer-
ides is performed by adipose triglyceride lipase (ATGL). Subse-
quently, hormone-sensitive lipase (HSL) catalyzes the conversion 
of diacylglycerides to monoacylglycerides, while monoacylglyc-
erol lipase (MGL) converts monoacylglycerides to glycerol. Con-
sistent with the differences in FFA and glycerol levels documented 
in Figure 4A, the lipolytic activity in WAT explants was highest 
in SORLA KO and lowest in SORLA Tg animals (Figure 4B). We 
also quantified esterase activity, an activity that is unique to HSL 
and not seen for ATGL and MGL. Esterase (HSL) activity in the 
explants showed the same inverse correlation with SORLA levels 
as the lipase activity (Figure 4C).
evance of SORLA expression levels in adipocytes for control of 
body weight in humans was further substantiated by studies in 
obese human subjects, documenting a clear correlation of BMI 
with levels of SORL1 transcript (Figure 3A) and SORLA protein 
(Figure 3B) in visceral adipose tissue.
SORLA levels determine lipolytic activity in WAT. To uncover 
the mechanisms of SORLA in controlling adipocyte metabolism, 
we studied the lipolytic activity in adipose tissue explants from 
SORLA KO and SORLA WT as well as from SORLA WT/Cre and 
SORLA Tg mice in detail. To exclude confounding secondary 
effects from dietary stress and pronounced obesity, we performed 
these analyses that readily document the SORLA-dependent 
effect on fat mass in tissues from mice on normal chow (Figure 1C 
and Figure 2B). As no obvious phenotypic differences were seen 
when comparing control littermates without (SORLA WT) or with 
the Cre transgene (SORLA WT/Cre) using unpaired Student’s t 
test (P > 0.05), data obtained in both control lines in all subsequent 
studies were combined in a control strain data set (SORLA CTR).
Figure 3. SORL1 transcript and protein levels in human WAT correlate 
with BMI. (A) Levels of SORL1 transcripts were determined by q-PCR in 
human visceral WAT and calculated as relative to the levels of 18S rRNA 
in the samples. SORL1 levels are positively correlated with BMI. *P < 0.05, 
1-way ANOVA. (B) SORLA protein levels were determined in human visceral 
WAT by ELISA and positively correlated with BMI of sample donors using 
linear regression and correlation analysis (P = 0.013). The inset depicts 
Western blot analysis of SORLA levels in subcutaneous WAT of individuals 
with the indicated BMI.
Table 2. Plasma lipid parameters in mice on HFD
Lipid parameters SORLA WT SORLA KO
FFAs (nmol/ml) 973.34 ± 69.28 (n = 9) 978.95 ± 83.70 (n = 10) NS
Triacylglyceride (mg/dl)  67.5 ± 9.98 (n = 9)  58.15 ± 3.01 (n = 10) NS
Free cholesterol (μg/ml) 511.98 ± 33.45 (n = 9) 426.88 ± 46.86 (n = 10) NS
Lipid parameters SORLA WT/Cre SORLA Tg
FFAs (nmol/ml) 731.98 ± 102.90 (n = 9) 761.98 ± 102.90 (n = 9) NS
Triacylglyceride (mg/dl)  58.58 ± 2.74 (n = 9)  65.09 ± 5.21 (n = 9) NS
Free cholesterol (μg/ml) 353.47 ± 26.90 (n = 9) 475.15 ± 34.92 (n = 9) P < 0.05
Levels of the indicated lipids were determined using commercial ELISA kits in plasma of male mice on a HFD for 15 weeks (as detailed in Methods). 
Unpaired Student’s t tests were used. Comparison of Sorl1+/+ (SORLA WT) and Sorl1–/– (SORLA KO) mice and comparison of Sorl1+/+ Rosa26+/+ Tg(Adipoq-Cre)1Evdr/J 
(SORLA WT/Cre) and Sorl1+/+ Rosa26TgSORL1WT Tg(Adipoq-Cre)1Evdr/J (SORLA Tg) mice.
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SORLA promotes insulin-dependent inhibition of lipolysis in adi-
pocytes. The rate of lipolysis in adipose tissue is subject to tight 
regulation by several hormones (17). Chief factors are catechol-
amines (e.g., norepinephrine [NE]) that act through β-adrenergic 
receptors to stimulate cAMP production by adenylate cyclase 
(AC). In turn, cAMP activates PKA, resulting in increased HSL 
phosphorylation and activity. Stimulation of lipolysis in adipose 
tissue is counteracted by IR signaling that activates PKB (AKT). 
AKT promotes phosphodiesterase 3β (PDE3β) activity that con-
verts cAMP to AMP and inhibits PKA action. To identify the sig-
naling pathway affected by SORLA in adipocytes, we performed 
studies in gonadal fat explants from mice on normal chow. When 
explants from SORLA KO, SORLA WT, SORLA WT/Cre, and 
HSL is the rate-limiting enzyme for regulated lipolysis in adi-
pocytes. Its activity is controlled through phosphorylation by PKA, 
enabling the phosphorylated (activated) enzyme to access its 
substrate in lipid droplets (15, 16). In line with having the highest 
lipolytic activity, SORLA KO explants also contained significantly 
higher levels of total and of phosphorylated HSL (p-HSL) than 
SORLA CTR and Tg explants (Figure 4, D–F). Also, the amount 
of cAMP-dependent PKA catalytic α subunit (activated PKA) was 
highest in SORLA KO adipose tissue, as documented by Western 
blotting (Figure 4, D–F). The differences in HSL protein and activ-
ity were not explained by alterations in gene transcription, as Hsl 
transcript levels were lowest in SORLA KO, intermediate in SORLA 
CTR, and highest in SORLA Tg (Supplemental Figure 8C).
Figure 4. SORLA levels in WAT are inversely correlated with lipolytic enzyme activities. (A) Explants of gonadal WAT were generated from mice of the 
indicated genotypes and kept in culture for 72 hours. Levels of FFAs in the tissue (FFA intracellular) and the supernatant (FFA released) as well as levels 
of glycerol released negatively correlate with SORLA levels. n = 6–11 animals per genotype; *P < 0.05; ***P < 0.001, 1-way ANOVA. (B and C) Levels of 
lipase (B) and esterase activities (C) in adipocytes isolated from gonadal WAT were determined as described in Supplemental Methods and are expressed 
as a percentage of signal increase at OD400nm over time. Both enzyme activities are inversely correlated with SORLA levels, as seen in comparisons of 
SORLA KO, SORLA CTR, and SORLA Tg animals. n = 6–7 animals per genotype. P < 0.001, 2-way ANOVA. Data in A–C were determined separately in 
SORLA WT and SORLA WT/Cre animals. As no statistically significant difference in any parameter was noted, these 2 genotype groups were combined 
as the control group (CTR). P > 0.05, unpaired Student’s t test. (D and E) Levels of SORLA, total HSL and p-HSL, and cAMP-dependent protein kinase A 
catalytic α subunit (cAMP-Cα) (activated PKA) as well as calnexin (loading control) were determined by Western blot analysis in gonadal WAT of SORLA 
WT and SORLA KO animals (D) or in SORLA WT/Cre and SORLA Tg animals (E). Representative samples from 3 animals per genotype are shown. (F) 
Signal intensities for the indicated proteins in SORLA KO and SORLA Tg were determined by densitometric scanning of replicate blots and expressed as 
relative value compared with the respective control group (SORLA WT or SORLA WT/Cre) set to 100%. Both control groups are jointly referred to as CTR. 
A significant increase in HSL, p-HSL, and cAMP-Cα levels in SORLA KO as compared with CTR and Tg mice was noted. n = 10–12 animals per genotype.  
*P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA.
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SORLA Tg mice were treated with NE or the β-adrenergic recep-
tor agonist isoproterenol (IPT), they displayed the same relative 
increase in FFA production (Figure 5, A and B). Also, simultaneous 
treatment with forskolin, which activates AC, and with 3-isobutyl-
1-methylxanthine (IBMX), which inhibits PDE3β, stimulated FFA 
mobilization equally well in all 3 genotypes (Figure 5, C and D). 
While SORLA activity did not affect prolipolytic pathways, it had a 
profound effect on insulin-mediated inhibition of lipolysis. Thus, 
following acute treatment with insulin, levels of FFAs dropped in 
SORLA Tg tissues by 50%, but only by about 30% in SORLA WT 
and SORLA KO (Figure 5, E and F). The ability of SORLA to pro-
mote insulin-mediated suppression of lipolysis was also seen in 
primary adipocytes differentiated from preadipocytes of gonadal 
adipose tissue pads of the various genotypes (Figure 5G). Again, 
acute stimulation with insulin suppressed release of FFAs more 
strongly in SORLA CTR and SORLA Tg compared with SORLA 
KO adipocytes (Figure 5, H and I).
SORLA modulates insulin signaling in WAT and affects energy 
homeostasis in mice. Having established the ability of SORLA to 
promote insulin-mediated inhibition of lipolysis in explants, we 
tested the effect of this agonistic receptor action on insulin sig-
naling in WAT in vivo. To do so, we acutely injected SORLA Tg, 
SORLA WT, SORLA WT/Cre, and SORLA KO mice with insulin 
and quantified the response to hormonal stimuli in WAT by West-
ern blot analysis of IR pathway components. Within 15 minutes, 
all genotypes responded to insulin application with the expected 
increases in phosphorylated IR (p-IR) and AKT (p-AKT) levels 
(Supplemental Figure 9A). However, the extent of pathway acti-
Figure 5. SORLA levels in WAT positively correlate with the extent of insulin-induced suppression of lipolysis. (A–F) Explants of gonadal WAT were gener-
ated from 4 genotype groups (SORLA KO, SORLA WT, SORLA WT/Cre, SORLA Tg) and treated in culture with the indicated substances. Thereafter, levels of 
FFAs in the tissues were determined. Panels B, D, F, and I display the concentration of FFAs for each genotype under untreated and treated conditions. Pan-
els A, C, E, and H give the extent of response for each genotype expressed as percentage change compared with the respective untreated genotype control 
(absolute values shown in panels B, D, F, and I and set to 100% in panels A, C, E, and H). As no difference in any of the parameters was observed comparing 
SORLA WT and SORLA WT/Cre animals, both genotypes were combined as control (CTR) lines. (A–D) Gonadal WAT from SORLA KO, SORLA Tg, and CTR 
(SORLA WT and SORLA WT/Cre) mice responded to treatment (48 hours) with NE and IPT (A and B) or with forskolin and IBMX (C and D) with a comparable 
increase in FFA production. (E and F) Treatment with insulin for 60 minutes showed a genotype-dependent effect on FFA production with a strong reduction 
in SORLA Tg (51% compared with control tissue), but a lesser decrease in SORLA KO (69%) and CTR (65%) explants. n = 6–14 animal per genotype. *P < 0.05; 
**P < 0.01; ***P < 0.001, unpaired Student’s t test (A, C, and E); 1-way ANOVA (B, D, and F). (G) Appearance of primary adipocytes derived from preadipo-
cytes of the indicated Sorl1 genotypes (oil red O staining). Original magnification, ×40. (H and I) Primary adipocytes of the indicated Sorl1 genotypes were 
treated with insulin for 30 minutes and the levels of released FFAs determined. H displays the concentration of FFAs for each genotype in the untreated and 
insulin-treated condition. I gives the extent of response for each genotype expressed as percentage of change compared with the respective untreated geno-
type control (set to 100%). Insulin-dependent suppression of FFA production is stronger in cells expressing SORLA (CTR and Tg) than in adipocytes lacking 
the receptor (KO). 10–12 animals per genotype. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired Student’s t test (H); 1-way ANOVA (I).
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vation following acute insulin stimulation was different and pos-
itively correlated with SORLA levels (Figure 6, A and B). Thus, 
the amounts of p-IR (Figure 6C) and p-AKT (Figure 6D) were 
higher in SORLA Tg than in SORLA CTR and SORLA KO mice. 
Also, PDE3β (Figure 6E) exhibited the highest levels in SORLA 
Tg and the lowest in SORLA KO. Conversely, levels of activated 
PKA were lowest in SORLA Tg and highest in SORLA KO (Fig-
ure 6F), in line with insulin signaling counteracting PKA-medi-
ated activation of HSL. Levels of endogenous SORLA in SORLA 
WT mice significantly increased with acute insulin application 
(Supplemental Figure 9, A and B), a phenomenon caused by post-
transcriptional mechanisms, as Sorl1 transcript levels remained 
unchanged (Supplemental Figure 9C). Changes in IR signaling 
rates were the cause of altered lipolytic activity in the various gen-
otype groups, as other pathways affected by SORLA activity (e.g., 
bone morphogenetic protein signaling) (18) were not changed 
when comparing SORLA KO, SORLA CTR, and SORLA Tg mice 
(Supplemental Figure 10).
Altered levels of insulin signaling in adipose tissue affected 
the energy balance of the mice, as documented by analyzing 
metabolic parameters in SORLA KO and SORLA WT as well as 
in SORLA WT/Cre and SORLA Tg animals. As shown in Figure 
7, basic metabolic rates, expressed as respiratory exchange ratio 
(RER), differed significantly, being highest in SORLA Tg, lowest 
in SORLA KO, and intermediate in SORLA WT and SORLA WT/
Cre (SORLA CTR). Relatively higher levels of the RER (VCO2/
O2) indicate preferred carbohydrate oxidation, whereas lower 
levels indicate preferred lipid oxidation. Accordingly, our find-
ings suggested a relative shift in metabolic fuel from carbohy-
drates in SORLA Tg to lipids in SORLA KO mice on normal chow. 
This conclusion was in line with the higher lipolytic activity in 
WAT of receptor-deficient as compared with receptor-overex-
pressing animals shown in Figure 4, A–C. Consistent with what 
has been reported for many mouse strains before (19, 20), the 
RER decreased in all mice on HFD with no obvious difference 
between SORLA genotype groups (Supplemental Figure 11A). 
Also, on HFD, the levels of activity and heat production were 
slightly decreased in SORLA CTR and SORLA Tg as compared 
with SORLA KO mice, likely reflecting the increased body 
weight in the obese strains (Supplemental Figure 11, C and D). 
Food intake was unchanged (Supplemental Figure 11B).
SORLA promotes insulin signaling to decrease lipolytic activ-
ity in cells. To further explore the cellular mechanism of SORLA 
in IR signaling, we used CHO cells, a model commonly used to 
study lipolysis (21). We compared parental CHO cells that do 
not express endogenous SORLA with CHO cells stably overex-
pressing the human receptor (CHO-S) (Supplemental Figure 12, 
A and B). When grown in normal medium, CHO-S cells showed 
a significant accumulation of intracellular lipid droplets as com-
pared with parental CHO cells (Figure 8A), a difference that was 
exacerbated by adding oleic acid to the culture medium (Figure 
8B). Less lipid accumulation in CHO cells lacking SORLA resem-
bled the phenotype seen in WAT of SORLA KO mice. As such, 
this observation supported the appropriateness of CHO cells for 
studying SORLA action in lipolysis. Our conclusion was con-
firmed by documenting decreased lipolytic activity in CHO-S as 
Figure 6. SORLA alters levels of IR signaling in WAT in vivo. SORLA KO, SORLA WT, SORLA WT/Cre, and SORLA Tg mice were injected with insulin (40 
μg/kg body weight), and gonadal WAT was dissected 15 minutes later. Levels of the indicated proteins in these tissues were determined by Western blot-
ting (A and B) and by densitometric scanning of replicate blots (C–F). Protein levels in SORLA KO (A) or in SORLA Tg (B) mice were compared separately 
to their respective SORLA WT and SORLA WT/Cre control groups. Levels in both control lines were set to 100% and jointly referred to as CTR in C–F. 
The amount of SORLA positively correlates with the relative levels of p-IR (p-IR/total IR; C), p-AKT (p-AKT/total AKT; D), and PDE3β (E) in SORLA Tg as 
compared with SORLA CTR and SORLA KO mice. Also, SORLA levels negatively correlate with levels of cAMP-Cα (F) in these mice. n = 15–32 animals per 
genotype. *P < 0.05; **P < 0.01, 1-way ANOVA. The immunodetection of SORLA in A was derived from duplicate samples run on a separate gel.
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cytes. Thus, the physical interaction of endogenous SORLA with 
the IR was documented by coimmunoprecipitation of the IR with 
anti-SORLA antiserum from WAT of SORLA WT but not from 
SORLA KO animals (Figure 9D). To assess the effect of endog-
enous SORLA on the surface exposure of the IR, we differenti-
ated murine embryonic fibroblasts (MEFs) from SORLA WT and 
SORLA KO mice to adipocytes. While SORLA was not expressed 
in fibroblasts, differentiation into adipocytes resulted in massive 
induction of receptor expression in SORLA WT cells (Supplemen-
tal Figure 13). Coexpression with SORLA resulted in significantly 
higher levels of the IR being exposed on the surface of SORLA 
WT adipocytes compared with that of SORLA KO cells, as shown 
by surface biotinylation experiments (Figure 9, E and F). Finally, 
enhanced cell surface exposure of the IR in adipocytes overex-
pressing SORLA was documented by immunostaining of SORLA 
WT/Cre and SORLA Tg primary adipocytes not permeabilized 
with detergent (Supplemental Figure 12E).
SORLA-mediated sorting prevents lysosomal catabolism and 
facilitates cell surface reexposure of the IR. Increased surface expo-
sure of the endogenous IR in CHO-S cells and primary adipocytes 
was caused by altered trafficking of the IR in the presence of the 
sorting receptor SORLA. As seen in cells permeabilized with Tri-
ton X-100 prior to immunostaining, the IR showed a predomi-
nant perinuclear (Golgi like) pattern in CHO-S, but a dispersed 
vesicular pattern in CHO cells lacking SORLA (Supplemental 
Figure 12D). Altered sorting of the IR by SORLA was confirmed 
by costaining of the IR with markers of endocytic and secretory 
compartments (Supplemental Figure 14A) and by determining the 
extent of colocalization by Pearson’s correlation coefficient (Sup-
plemental Figure 14B). Compared with CHO cells, the presence of 
SORLA in CHO-S increased the levels of the IR in the trans-Golgi 
network (TGN) (marker VTI1B) and in Golgi-destined vesicles 
(marker AP1). It also raised IR levels in vesicles directing cargo to 
the cell surface, including secretory vesicles (marker VTI1A) and 
recycling endosomes (marker RAB11). In contrast, while the levels 
of the IR in CHO-S were increased in early endosomes (marker 
EEA1), no increase was seen in RAB9-positive late endosomes 
(Supplemental Figure 14B). These data indicate that SORLA pro-
motes recycling of internalized IR molecules via the Golgi to the 
cell surface, avoiding a late endosomal/lysosomal fate for the IR.
Binding of insulin to the IR induces internalization and lyso-
somal degradation of the receptor in adipocytes, a means for 
downregulating this signaling pathway after stimulation (22, 23). 
To explore the consequence of insulin-dependent sorting of the 
IR in the presence or absence of SORLA, we tagged IR molecules 
on the surface of CHO and CHO-S cells at 4°C using anti-IR anti-
serum. Subsequently, insulin was added to the medium and the 
cells were shifted to 37°C to track IR internalization by immuno-
compared with parental CHO cells (Figure 8C). Decreased lipoly-
sis coincided with increased levels of PDE3β and decreased lev-
els of activated PKA in CHO-S (Figure 8, D and E). These differ-
ences in insulin signaling components were due to an increased 
sensitivity of CHO-S cells to insulin stimulation. This effect was 
shown by treatment of cells with insulin for 15 minutes, reduc-
ing lipolysis more strongly in CHO-S than in CHO cells (Figure 
8F). While insulin treatment caused the expected decreases in 
activated PKA levels in CHO-S cells, the response in CHO cells 
lacking SORLA was blunted, as activated PKA levels remained 
unchanged compared with those in CHO cells not treated with 
insulin (Figure 8, G and H).
SORLA interacts with the IR to promote its cell surface exposure. 
Next, we investigated the molecular interaction of the endog-
enous IR with SORLA in CHO-S cells. As shown in Supplemental 
Figure 12C, SORLA colocalized with the endogenous IR in these 
cells. Moreover, both proteins directly interacted, as documented 
by coimmunoprecipitation of the IR with anti-SORLA antiserum 
from CHO-S cells (Figure 9A). Interaction with SORLA strongly 
increased the surface exposure of the IR. This effect was docu-
mented by biotinylation of surface proteins in CHO and CHO-S 
cells and by semiquantitative Western blot analysis of the amount 
of biotinylated IR precipitated from both cell lines. While the 
amount of total IR in the CHO-S lysate was even slightly decreased, 
the amount of receptor on the cell surface was increased by 60% 
as compared with that in CHO (Figure 9, B and C). Enhanced sur-
face exposure of the IR in the presence of SORLA was substanti-
ated by comparing immunosignals for the IR in CHO-S and CHO 
cells not permeabilized with Triton X-100 (Supplemental Figure 
12D; panel without Triton X-100).
The functional interaction of SORLA with the IR seen in 
CHO-S cells was confirmed for the endogenous proteins in adipo-
Figure 7. SORLA activity affects basic metabolic rates in vivo. (A) Basic 
metabolic rates were determined in SORLA KO, SORLA WT, SORLA WT/
Cre, and SORLA Tg mice and expressed as RER. As no statistically signifi-
cant difference were noted comparing SORLA WT and SORLA WT/Cre ani-
mals, both genotypes were combined as control (CTR) group. (B) The RER 
is displayed separately for day (6 am–6 pm) and night (6 pm–6 am) as well 
as combined. The data show a significant increase in RER with increasing 
levels of SORLA when comparing SORLA KO, SORLA CTR, and SORLA Tg 
animals. n = 5–7 animals per genotype. *P < 0.05, 1-way ANOVA.
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Prevention of IR targeting to late endosomes/lysosomes by 
SORLA markedly increased the half-life of this receptor follow-
ing stimulation by insulin. This effect was documented by bioti-
nylation of the IR on the surface of CHO and CHO-S cells and by 
quantification of the tagged receptor molecules at various time 
points after stimulation of the cells with insulin by Western blot-
ting. As shown in Figure 12, the amount of IR molecules originat-
ing from the cell surface decreased significantly faster in CHO as 
compared with CHO-S cells. Decay of IR molecules was blocked 
to a similar extent in both cell lines by application of a lysosomal 
inhibitor cocktail (leupeptin, pepstatin, and chloroquine).
Taken together, our data from CHO cells and primary adi-
pocytes uncovered the molecular mechanism whereby SORLA 
acts as a unique sorting factor that redirects internalized IR 
molecules back to the cell surface, thereby preventing lysosomal 
catabolism of the IR and strengthening insulin signal reception 
in adipose tissue.
cytochemistry. Within 20 minutes, application of insulin induced 
a shift of surface-localized IR molecules to intracellular compart-
ments in CHO and CHO-S cells (Figure 10A). While the kinetics 
of internalization was comparable in both cell types, the fate of 
the internalized IR molecules was quite different, as documented 
by costaining for subcellular marker proteins. As exemplified for 
RAB11 by immunofluorescence microscopy in Figure 10A and 
quantified for RAB11 and RAB9 in Figure 10, B and C, the pres-
ence of SORLA promoted accumulation of the IR in recycling 
endosomes (RAB11), but reduced IR targeting to late endosomes 
(RAB9). The very same activity of SORLA was also observed in 
primary adipocytes tagged for endogenous IR molecules on the 
cell surface using anti-IR antiserum at 4°C (Figure 11A). Within 30 
minutes after insulin treatment and shift to 37°C, surface-tagged 
IR molecules preferentially routed to RAB11-positive recycling 
endosomes in SORLA Tg adipocytes, but to RAB9-positive late 
endosomes in SORLA KO cells (Figure 11, B and C).
Figure 8. SORLA enhances IR signaling and lipid accumulation in CHO cells. (A and B) Oil red O staining of parental CHO cells and CHO-S cells. Cells grown 
in normal medium (A) or in medium containing 100 μM oleic acid (B). Accumulation of intracellular lipid droplets (red) is more pronounced in CHO-S as 
compared with CHO cells under both conditions. Original magnification, ×40. (C) Lipase activity in CHO and CHO-S cells expressed as percentage of signal 
increase at OD400nm over time. Lipolytic activity is significantly lower in CHO-S as compared with CHO cells. n = 10. P < 0.05 for genotypes; P < 0.05 for 
interaction, matched 2-way ANOVA. (D and E) Densitometric scanning of replicate Western blots (as exemplified in D) documents significantly increased 
levels of PDE3β and decreased levels of cAMP-Cα in CHO-S as compared with CHO cells. n = 6–11. *P < 0.05; ***P < 0.001, unpaired Student’s t test. (F) 
Lipase activity in CHO and CHO-S cells treated with 10 μg/ml insulin for 15 minutes (expressed as percentage increase at OD400nm). The enzyme activity is 
significantly lower in CHO-S as compared with CHO cells. n = 10. P < 0.001 for genotypes; P < 0.001 for interaction, matched 2-way ANOVA. (G and H) CHO 
and CHO-S cells were treated with control medium or with medium containing 10 μg/ml insulin for 15 minutes and the amount of cAMP-Cα in cell extracts 
determined by Western blotting thereafter. Representative Western blots are shown in G. The results of densitometric scanning of replicate blots are 
given in H. CHO-S cells respond to insulin treatment with decreased levels of cAMP-Cα, whereas CHO cells lacking SORLA do not respond to insulin stimu-
lation. n = 6. **P < 0.01, unpaired Student’s t test.
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familial AD gene as well (11, 26). Now, our studies identified the 
IR as a target for SORLA-mediated protein sorting in adipocytes. 
Similarly to APP, interaction of the IR with SORLA redirected 
internalized IR molecules from early endosomes to the TGN 
and to cell surface–destined recycling compartments in the pres-
ence of insulin stimuli (Figures 10 and 11). This retrieval path-
way reduced the amount of IR molecules delivered to lysosomal 
catabolism (Figure 12) and increased the fraction of receptors 
reexposed on the cell surface (Figure 9).
SORLA-mediated sorting of the IR promotes insulin action in 
cells. Cellular trafficking of the IR has long been recognized as a 
mechanism to control insulin signaling (reviewed in ref. 27). Fol-
lowing binding of the hormone on the cell surface, complexes of 
IR and insulin undergo endocytosis that serves 2 purposes. First, 
it delivers receptor-ligand complexes to endosomes, a prereq-
uisite for signal transduction. Second, it moves receptor-ligand 
complexes to lysosomal compartments for catabolism, a means 
of downregulating signal reception. In CHO cells, SORLA activ-
ity promotes insulin-dependent suppression of lipolysis and 
accelerates lipid accumulation (Figure 8). The same mechanism 
is operable in adipocytes. In vivo, the presence of SORLA pro-
motes insulin-dependent signaling in WAT (Figure 6) and stimu-
lates insulin-induced suppression of lipolysis in adipose tissue 
explants (Figure 5, E and F) and primary adipocytes (Figure 5, 
H and I). Other pathways in control of lipolysis (e.g., through 
catecholamines) are not influenced by SORLA (Figure 5, A–D), 
Discussion
We have identified a regulatory pathway whereby SORLA facili-
tates cell surface exposure of the IR to increase insulin signaling 
and to reduce lipolytic activity in adipocytes. In mice, decreased 
lipolysis in WAT in the presence of SORLA promotes the accu-
mulation of triacylglycerides and exacerbates diet-induced obe-
sity, while loss of SORLA activity causes excessive lipolysis and 
a reduction in WAT mass. Genome-wide association of SORL1 
with obesity (2) and the correlation of SORLA protein levels in 
adipose tissue with BMI in human subjects shown here under-
line the clinical relevance of this receptor for disorders of the 
human metabolism.
SORLA is a sorting receptor for the IR. SORLA is a sorting 
receptor that shuttles between endosomes and the TGN to sort 
target proteins between endocytic and secretory compartments 
of the cell. Shuttling of SORLA is guided by the adaptors GGA, 
PACS1, and retromer, which bind to the cytoplasmic tail of the 
receptor and direct its movement from endosomes to the TGN 
and back (24, 25). The relevance of SORLA-mediated protein 
sorting has best been elucidated for APP in AD. SORLA-medi-
ated retrieval of APP from early endosomes to the TGN reduces 
the production of neurotoxic Aβ peptides, the cause of neurode-
generative processes in AD (6, 7). This protective action renders 
SORLA one of the major risk factors for sporadic AD known to 
date (8). The identification of mutations in SORL1 in cases with 
autosomal-dominant forms of the disease suggests SORLA as a 
Figure 9. SORLA interacts with the IR to increase cell surface exposure. (A) Parental CHO cells and CHO-S cells were subjected to immunoprecipitation 
using anti-SORLA antiserum. Input represents Western blot analyses of cell lysates prior to immunoprecipitation. IP depicts SORLA and IR in the precipi-
tate. Precipitation of SORLA from CHO-S (lane 1) results in coimmunoprecipitation of the IR. No (co)immunoprecipitation of SORLA and IR is seen in paren-
tal CHO cells lacking SORLA (lane 2) or in CHO-S cells without addition of anti-SORLA IgG (w/o IgG; lane 3). (B and C) Replicate layers of CHO and CHO-S cells 
were treated with sulfo-NHS-S-S-biotin and biotinylated surface proteins precipitated by streptavidin beads. The amount of IR in total cell lysates (total lev-
els) and in the biotinylated fraction (surface) was determined by Western blotting (B). Cell surface levels of the IR are increased in CHO-S as compared with 
parental CHO cells (relative levels set to 100%), as shown by densitometric scanning of replicate experiments (C). n = 10. ***P < 0.001, unpaired Student’s t 
test. (D) Coimmunoprecipitation of endogenous IR with endogenous SORLA from gonadal WAT of SORLA WT but not SORLA KO mice using anti-SORLA IgG 
(IP SORLA). Input documents levels of SORLA and IR in SORLA WT and SORLA KO WAT prior to immunoprecipitation. (E and F) MEFs from SORLA WT and 
SORLA KO mice were differentiated to adipocytes. Replicate layers of adipocytes were treated with sulfo-NHS-S-S-biotin and biotinylated surface proteins 
precipitated by streptavidin beads. The amount of IR in total cell lysates (total) and in the biotinylated fraction (surface) was determined by Western blot-
ting (E) and by densitometric scanning of replicate experiments (F). The total levels of the IR are unchanged, but the cell surface levels decreased in SORLA 
KO as compared with SORLA WT adipocytes (relative levels set to 100%). n = 6–7 per genotype. *P < 0.05, unpaired Student’s t test.
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SORLA for lipid homeostasis in vivo. However, contrary to pre-
vious hypotheses, our studies failed to support the significance 
of SORLA for systemic lipoprotein metabolism, as lipoprotein 
profiles were indistinguishable when comparing SORLA WT, 
SORLA WT/Cre, SORLA KO, and SORLA Tg mice on normal 
chow. Also, LpL activity in plasma and in tissues was unchanged 
when comparing Sorl1 genotypes. Rather than affecting the lev-
el of circulating lipoproteins, our studies identified the involve-
ment of SORLA in control of adipose tissue mass. A positive cor-
relation of SORLA levels with white adipose mass was seen in 
mice on normal chow (Figure 1C and Figure 2B) and was greatly 
exacerbated by feeding animals with HFD (Figure 1A and Figure 
2C). Also, transcript and protein levels for SORL1 in WAT cor-
related with BMI in humans (Figure 3).
Conceivably, the loss of expression of SORLA in many tis-
sues that normally express the receptor may contribute to the 
lean phenotype seen in SORLA KO animals. However, tissue-
specific overexpression of the receptor in adipocytes of SORLA 
Tg mice resulted in features that were the opposite of those seen 
in SORLA KO animals, including enhanced fat mass (Figure 2) 
and reduced lipolytic activity (Figure 4) as well as increased 
insulin-dependent signaling and reduced rates of lipolysis in pri-
mary adipocytes and adipose tissue explants (Figure 5) as well 
as in vivo (Figure 6). These findings strongly argue that loss of 
SORLA activity in adipocytes is the cause for the reduced adi-
pose tissue mass in SORLA KO animals.
All available evidence from studies in primary adipocytes, in 
murine and human WAT, and in in vivo experimentation in this 
study is consistent with a model whereby SORLA modulates the 
activity of the IR in adipocytes and determines the extent of insu-
lin-induced suppression of lipolysis. The progressive decrease in 
lipolytic activity from SORLA KO to SORLA CTR to SORLA Tg 
mice (Figure 4, A–C) coincides with a concomitant shift in the 
usage of carbohydrates over lipids as an energy source, as shown 
by the change in RER (Figure 7), documenting the impact of SOR-
LA levels on energy homeostasis in vivo.
Recently, a role for the soluble ectodomain of SORLA (called 
sLR11) in control of thermogenesis in mice has been reported. 
Specifically, sLR11 is proposed to act via the BMP receptor path-
way to suppress browning of WAT (18). Possibly, SORLA may 
assume different roles in control of systemic metabolism, includ-
ing action as a humoral factor. However, our data unambiguously 
document a cell-autonomous function for the full-length recep-
documenting the specificity of SORLA for insulin action in this 
cell type. Our data are most consistent with a model whereby 
SORLA directs the IR from early endosomes to recycling com-
partments (marked by VTI1A and RAB11) to prevent lysosomal 
breakdown of receptor molecules and to enhance their reexpo-
sure at the cell surface. Because SORLA increases the amount of 
IR in early endosomes (marked by EEA1), it may also facilitate 
signal transduction by promoting internalization of IR/ligand 
complexes into signaling endosomes.
SORLA determines WAT mass by affecting lipolysis rates in 
adipocytes. SORLA is expressed in a number of tissues relevant 
to energy metabolism, including the liver, skeletal muscle, 
and adipose tissue (refs. 28, 29, and Supplemental Figure 3A). 
Because SORLA binds apolipoproteins (30, 31) and LpL (10) in 
vitro, a role for this receptor in systemic lipoprotein metabolism 
had been proposed. Now, our studies in mouse models with loss 
or overexpression of this receptor substantiate the relevance of 
Figure 10. SORLA promotes cell surface recycling of internalized IRs in 
CHO cells. (A) Replicate layers of CHO and CHO-S cells were blocked at 4°C 
and cell surface–exposed IR molecules tagged with anti-IR IgG (0 minutes). 
Subsequently, 10 μg/ml insulin was added to the medium and cells shifted 
to 37°C. At time points 5, 15, and 20 minutes, the cells were fixed and 
costained for the tagged IR molecules (red) and recycling endosomal marker 
RAB11 (green). Colocalization of both proteins is seen in CHO-S (arrow-
heads) but not CHO cells after 20 minutes of chase. Original magnification, 
×60. (B and C) Experiments as exemplified in A were performed and the 
colocalization of the IR with RAB11 (B) and RAB9 (C) evaluated by Pearson’s 
correlation coefficient (r). The IR preferentially colocalized with RAB11 in 
CHO-S as compared with CHO cells. In contrast, colocalization of the IR with 
late endosomal marker RAB9 was reduced in CHO-S as compared with CHO 
cells. n = 20–30 cells. *P < 0.05; ***P < 0.001, 2-way ANOVA.
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effect of SORLA is already evident on normal chow and underlies 
the exacerbation of diet-induced obesity seen on a HFD. Distur-
bances in glucose handling (hyperinsulinemia, hyperglycemia) 
as well as advanced tissue pathology (adipose tissue hypertrophy, 
liver steatosis) in SORLA Tg mice on a HFD are secondary conse-
quences of overt obesity in these animals (Supplemental Figures 
6 and 7). They do not reflect a primary effect of SORLA on glucose 
homeostasis, as hypersensitivity to insulin seen in adipocytes of 
the SORLA Tg line is expected to facilitate rather than inhibit 
insulin action on glucose uptake.
The importance of insulin in determining lipolysis rates and, 
thereby, fat mass is underscored by mouse models and humans 
with alterations in the insulin pathway in adipocytes. For exam-
ple, targeted disruption of the gene encoding PDE3β, the PDE 
acting downstream of the IR in adipocytes, blocks insulin inhibi-
tion of lipolysis, thereby causing excessive lipolytic activity and 
a decrease in WAT mass in mice. The effect of PDE3β deficiency 
is specific for insulin-dependent control of lipolysis, as it does 
not alter glucose handling by adipocytes (33). Phosphatase and 
tensin homolog (PTEN) is an effector molecule that antagonizes 
insulin action through inhibition of AKT. Haploinsufficiency for 
PTEN in humans results in insulin hypersensitivity in adipose 
tissue and in obesity (34), while overexpression of the protein 
in mice reduces body fat accumulation (35). Apart from these 
observations in monogenic traits, epidemiological studies also 
show reduced lipolytic activity in adipose tissue of obese indi-
viduals (36–38), suggesting impaired mobilization of fat stores as 
tor in control of body weight and the incidence of obesity. This 
conclusion is supported by unchanged rates of transcription of 
genes proposed to act downstream of sLR11 in control of thermo-
genesis (18) in experimental conditions described here (Supple-
mental Figure 10).
SORLA, a regulator of energy balance and risk factor for human 
obesity. GWAS uncovered SORL1 as a gene associated with meta-
bolic phenotypes in humans and mouse models. In the longitudi-
nal Bogalusa Heart Study (2), SORL1 emerged as a top hit associ-
ated with the risk of obesity in children as they advance through 
adulthood. In the analysis of obesity traits in inbred strains of 
mouse, Sorl1 predicted body fat percentage (9), while global tran-
scriptome analysis in mice with diet-induced obesity identified 
Sorl1 as an adipocyte-specific gene responsive to caloric restric-
tion (32). Massive induction of Sorl1 expression in MEFs, as they 
differentiate to adipocytes, supports a pivotal role for this recep-
tor in adipocyte function. Expression of SORL1 is correlated with 
BMI in humans (Figure 3) and promoted by insulin in adipocytes 
(Supplemental Figure 9), reinforcing the relevance of this receptor 
for metabolic pathways in fat tissue.
What is the evidence that the ability of SORLA to modulate 
insulin-dependent rates of lipolysis in WAT explains the asso-
ciation of SORL1 with obesity in humans and mice? Foremost, 
this assumption is supported by our findings that the level of 
this receptor in SORLA KO, SORLA CTR, and SORLA Tg mice 
inversely correlates with the ability to mobilize lipids from adi-
pocytes (Figure 4) and predict fat tissue mass (Figure 2). This 
Figure 11. SORLA promotes recycling 
of internalized IR to the cell surface in 
primary adipocytes. (A) Replicate layers 
of primary adipocytes from SORLA KO 
and SORLA Tg mice were blocked at 4°C 
and cell surface–exposed IR molecules 
tagged with anti-IR IgG. Subsequently, 
10 μg/ml insulin was added to the 
medium and cells shifted to 37°C. At 
time points 5 and 30 minutes, the cells 
were costained for the tagged IR mol-
ecules (red) and markers RAB11 or RAB9 
(green). In SORLA KO adipocytes, the 
IR colocalizes preferentially with RAB9 
(see merged images in the insets). In 
contrast, in SORLA Tg adipocytes, the IR 
colocalizes with RAB11 after 30 minutes 
of chase. Both overview and inset images 
were acquired at ×60 magnification. 
Overview images were shrunk to 30% 
of original size. (B and C) Experiments 
as exemplified in A were performed and 
the colocalization of the IR with RAB11 
(B) and RAB9 (C) evaluated by Pear-
son’s correlation coefficient (r). The IR 
preferentially colocalized with RAB11 in 
SORLA Tg, but with RAB9 in SORLA KO 
adipocytes. n = 20–30 cells per genotype. 
*P < 0.05; ***P < 0.001, 2-way ANOVA.
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bohydrate). All experiments were performed in male mice from 30 
to 50 weeks of age. Details about the metabolic studies in mice are 
given in the Supplemental Methods.
Lipid analyses. Lipid levels in plasma and tissue were determined 
by Triacylglyceride Colorimetric Assay Kit (Cayman Chemical Com-
pany), Amplex Red Cholesterol Assay Kit (Molecular Biotechnology), 
or Free Fatty Acid Quantification Kit (BioVision) according to the 
manufacturers’ protocols. Lipoprotein profiles were characterized 
using FPLC (TNO Metabolic Health Research). Released glycerol was 
determined using the Free Glycerol Kit (Sigma-Aldrich). Analysis of 
FFAs by gas chromatography–mass spectrometry–based (GC-MS–
based) profiling is described in the Supplemental Methods.
Analysis of glucose metabolism. After overnight fasting, glucose 
levels in the mice were determined using a standard glucose meter 
(Contour, Bayer). The animals were then injected with glucose (i.p., 
2 g/kg body weight), and plasma glucose levels were determined at 
the indicated time points. Plasma insulin levels were determined with 
Ultra Sensitive Mouse Insulin ELISA (Crystal Chem).
Adipose tissue explants. Gonadal fat pads were removed from ani-
mals and washed in PBS. The fat pads were weighed, minced, and 
incubated in M199 medium (Gibco; Thermo Fisher Scientific) supple-
mented with 10% fetal bovine serum and 1% penicillin-streptomycin 
at 37°C and 5% CO2. After 2 hours, fresh medium was added and the 
explants incubated overnight. Next, the explants were treated with 
M199 medium supplemented with 1% fatty acid–free BSA, 1% peni-
cillin-streptomycin, and the indicated substances (500 μM IBMX, 5 
μg/ml insulin, 10 μM forskolin, 100 nM L [–] NE, 10 μM [–] IPT) for 
72 hours (chronic) or 60 minutes (acute). The amounts of intracellu-
lar and released FFAs or released glycerol were quantified using com-
mercial kits. The determination of lipases and esterase activities is 
detailed in the Supplemental Methods.
Analysis of human adipose tissue for SORLA expression. RNA from 
visceral adipose tissue was extracted using RNeasy Lipid Tissue 
Mini Kit (QIAGEN). Quantity and integrity of RNA was monitored 
with NanoVue plus Spectrophotometer (GE Healthcare). 1 μg total 
RNA was reverse transcribed with standard reagents (Life Technolo-
gies) and cDNA processed for TaqMan probe-based q-PCR using 
the QuantStudio 6 Flex Real-Time PCR System (Life Technologies). 
Expression of SORL1 (Hs00268342_m1), Ucp1 (Mm01244861_m1), 
Cideα (Mm00432554_m1), Elovl3 (Mm00468164_m1), and BmpR1b 
(Mm03023971_m1) were calculated by standard curve method and 
normalized to the expression of 18S rRNA (4352930E) or Gapdh 
(Mm99999915_g1) (Life Technologies).
a primary risk factor for the development of excess body fat. Our 
studies have substantiated the relevance of lipolytic rate for risk 
of obesity and a central role for SORLA as a sorting factor for the 
IR in this pathology. Overall, our findings also document a genetic 
link between obesity and neurodegeneration to converge on this 
sorting receptor pathway.
Methods
Study participants. For quantitative PCR (q-PCR) analysis, paired 
samples of visceral whole adipose tissue were obtained from 362 
individuals (246 women and 116 men). The age ranged from 19 to 
93 years. BMI was calculated by weight (kg) divided by square of 
height (m). All adipose tissue samples were collected during open 
or laparoscopic abdominal surgery, immediately frozen in liquid 
nitrogen, and stored at –80°C. Where sufficient tissue was available 
for protein extraction, specimens were also used for SORLA protein 
quantification by ELISA.
Animal experimentation. Mice with targeted disruption of Sorl1 
(Sorl1–/–) (6) or carrying a cDNA encoding WT human SORLA in 
the Rosa26 locus (Sorl1+/+ Rosa26TgSORL1WT) (11) have been described. 
Sorl1+/+ Rosa26TgSORL1WT animals were crossed with the Tg(Adipoq-Cre)1Evdr/J 
line (JAX 010803; The Jackson Laboratory) to direct SORLA over-
expression to adipocytes. All lines were kept by breeding of het-
erozygous animals, and all studies were performed comparing lit-
termates. Specifically, Sorl1–/– (referred to as SORLA KO) mice were 
compared with Sorl1+/+ littermates (referred to as SORLA WT). 
Sorl1+/+ Rosa26TgSORL1WT Tg(Adipoq-Cre)1Evdr/J (referred to as SORLA Tg) 
mice were compared with Sorl1+/+ Rosa26+/+ Tg(Adipoq-Cre)1Evdr/J litter-
mates (referred to as SORLA WT/Cre). No discernible phenotypic 
differences were seen when comparing SORLA WT and SORLA 
WT/Cre control groups. Thus, where applicable, both strains were 
combined into 1 control cohort (referred to as SORLA CTR) when 
testing Sorl1 gene-dosage effects in SORLA KO versus SORLA Tg 
genotypes. Animals were kept on a standard mouse chow (4.5% 
crude fat, 39% carbohydrates) or a HFD (35% crude fat, 10% car-
Figure 12. SORLA reduces lysosomal degradation of internalized IR mole-
cules. (A) Cell surface proteins in cultures of CHO and CHO-S cells were bio-
tinylated. Subsequently, 10 μg/ml insulin was added to the cells and the 
biotinylated proteins precipitated from cell lysates at the indicated time 
points using streptavidin. The amount of endogenous IR in the precipitate 
was determined by Western blot analysis. Where indicated, the lysosomal 
inhibitor (lyso. inh.) cocktail of leupeptin, pepstatin, and chloroquine was 
absent (w/o) or included (w/) in the cell medium. (B) Densitometric scan-
ning of replicate blots as exemplified in A documents faster turnover of IR 
molecules originating from the cell surface in CHO as compared with CHO-S 
cells. No difference in half-life of the IR was observed when the lysosomal 
activity in the CHO and CHO-S cells was blocked by the lysosomal inhibi-
tors. P < 0.05 for genotypes (w/o lysosomal inhibition); not significant for 
genotypes (with lysosomal inhibition). Unmatched 2-way ANOVA.
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sent before taking part in this study. All experiments involving mice 
were conducted following approval by local authorities of the Federal 
State of Berlin (X9012/12; G0339/12).
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